HYPERGONADOTROPIC HYPOGONADISM,
PROGRESSIVE EARLY-ONSET SPINOCEREBELLAR ATAXIA,
AND LATE-ONSET SENSORINEURAL HEARING LOSS:
CASE REPORT AND LITERATURE REVIEW
Sarikaya E,1 Ensert CG,2 Gulerman HC1
*Corresponding Author: Esma Sarikaya, Centre for Reproductive Medicine, Zekai Tahir Burak Women’s
Health Research and Education Hospital, Talatpasa Bulvari Hamamonu 06230, Ankara, Turkey; Tel.: +90-312-
310-3100; Fax: +90-312-312-4931; E-mail: sudesarikaya@hotmail.com
page: 77
|
|
REFERENCES
1. Holmes GA. Form of familial degeneration of the cerebellum.
Brain. 1908; 30(4): 466-489.
2. Bösze P, Skripeczky K, Gaál M, Tóth A, László J. Perrault’s
syndrome in two sisters. Am J Med Genet. 1983;
16(2): 237-241.
3. Amor DJ, Delatycki MB, Gardner RJ, Storey E. New
variant of familial cerebellar ataxia with hypergonadotropic
hypogonadism and sensorineural deafness. Am J
Med Genet. 2001; 99(1): 29-33.
4. Georgopoulos NA, Papapetropoulos S, Chroni E, Papadeas
ES, Dimopoulos PA, Kyriazopoulout V, Davis MB, Eunson L, Kourounis G, Tzingounist VA. Spinocerebellar
ataxia and hypergonadotropic hypogonadism
associated with familial sensorineural hearing loss. Gynecol
Endocrinol. 2004; 19(2): 105-110.
5. Pierce SB, Walsh T, Chisholm KM, Lee MK, Thornton
AM, Fiumara A, Opitz JM, Levy-Lahad E, Klevit
RE, King MC. Mutations in the DBP-deficiency protein
HSD17B4 cause ovarian dysgenesis, hearing loss, and
ataxia of Perrault syndrome. Am J Hum Genet. 2010;
87(2): 282-288.
6. Fehlow P, Walther F. Richards-Rundle syndrome. Klin
Paediatr. 1991; 203(3): 184-186.
7. Welsh LW. Alström syndrome: progressive deafness
and blindness. Ann Otol Rhinol Laryngol. 2007; 116(4):
281-285.
8. Mathis S, Paquis V, Mesnage V, Balaboï I, Gil R, Gilbert
B, Neau JP. Wolfram’s syndrome presenting as a
cerebellar ataxia Rev Neurol. 2007; 163(2): 197-204.
9. Finsterer J. Mitochondriopathies. Eur J Neurol. 2004;
11(3): 163-186.
10. Nishi Y, Hamamoto K, Kajiyama M, Kawamura I. The
Perrault syndrome: clinical report and review. Am J
Med Genet. 1988; 31(3): 623-629.
11. Ikezoe K, Yamada A, Takeuchi H, Miki H, Katanaka J.
A case of early onset cerebellar ataxia with hearing loss,
mental disturbance and primary hypogonadism. Rinsho
Shinkeigaku. 1992; 32(9): 1032-1034.
12. De Michele G, Filla A, Striano S, Rimoldi M, Campanella
G. Heterogeneous findings in four cases of cerebellar
ataxia associated with hypogonadism (Holmes’ type
ataxia). Clin Neurol Neurosurg. 1993; 95(1): 23-28.
13. Linssen WH, Van den Bent MJ, Brunner HG, Poels PJ.
Deafness, sensory neuropathy, and ovarian dysgenesis:
a new syndrome or a broader spectrum of Perrault syndrome?
Am J Med Genet. 1994; 51(1): 81-82.
14. Koskinen T, Pihko H, Voutilainen R. Primary hypogonadism
in females with infantile onset spinocerebellar
ataxia. Neuropediatrics. 1995; 26(5): 263-266.
15. Gottschalk ME, Coker SB, Fox LA. Neurologic anomalies
of Perrault syndrome. Am J Med Genet. 1996;
65(4): 274-276.
16. Fiumara A, Sorge G, Toscano A, Parano E, Pavone L,
Opitz JM. Perrault syndrome: evidence for progressive
nervous system involvement. Am J Med Genet A. 2004;
128(3): 246-249.
17. McCarthy DJ, Opitz JM. Perrault syndrome in sisters.
Am J Med Genet. 1985; 22(3): 629-631.
18. Kobe C, Kracht LW, Timmermann L, Bachmann J,
Schmidt MC. Perrault Syndrome with progressive
nervous system involvement. Clin Nucl Med. 2008;
33(12): 922-924.
19. Marlin S, Lacombe D, Jonard L, Leboulanger N, Bonneau
D, Goizet C, de Villemeur TB, Cabrol S, Houang M,
Moatti L, Feldmann D, Denoyelle F. Perrault syndrome:
report of four new cases, review and exclusion of candidate
genes. Am J Med Genet A. 2008;146(5):661-664.
20. Pallister PD, Opitz JM. 1979. The Perrault syndrome:
Autosomal recessive ovarian dysgenesis with facultative,
non-sex-limited sensorineural deafness. Am J Med
Genet. 4(3): 239-246.
21. Anttonen AK, Mahjneh I, Hämäläinen RH, Lagier-
Tourenne C, Kopra O, Waris L, Anttonen M, Joensuu T,
Kalimo H, Paetau A, Tranebjaerg L, Chaigne D, Loenig
M, Eeg-Olofsson O, Udd B, Somer M, Somer H, Lehesjoki
AE. The gene disrupted in Marinesco-Sjögren
syndrome encodes SIL1, an HSPA5 cochaperone. Nat
Genet 2005; 37(12): 1309-1311.
22. Beysen D, De Paepe A, De Baere E. FOXL2 mutations
and genomic rearrangements in BPES. Hum Mutat.
2009; 30(2): 158-169.
23. de Launoit Y, Adamski J. Unique multifunctional HSD17B4
gene product: 17beta-hydroxysteroid dehydrogenase
4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/
hydratase involved in Zellweger syndrome. J
Mol Endocrinol. 1999; 22(3): 227-240.
24. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial
disease. Dev Disabil Res Rev. 2010; 16(2):183-188.
25. Gempel K, Topaloglu H, Talim B, Schneiderat P,
Schoser BG, Hans VH, Pálmafy B, Kale G, Tokatli A,
Quinzii C, Hirano M, Naini A, DiMauro S, Prokisch
H, Lochmüller H, Horvath R. The myopathic form of
coenzyme Q10 deficiency is caused by mutations in
the electron-transferring-flavoprotein dehydrogenase
(ETFDH) gene. Brain. 2007; 130(Pt. 8): 2037-2044.
26. Finsterer J. Ataxias with autosomal, X-chromosomal
or maternal inheritance.Can J Neurol Sci. 2009; 36(4):
409-428.
27. Matsunaga T. Value of genetic testing in the otological
approach for sensorineural hearing loss. Keio J Med.
2009; 58(4): 216-222.
28. Wenstrom KD. Fragile X and other trinucleotide repeat
diseases. Obstet Gynecol Clin North Am. 2002; 29(2):
367-388.
29. Girard D, Petrovsky N. Alström syndrome: insights into
the pathogenesis of metabolic disorders. Nat Rev Endocrinol.
2011; 7(2): 77-88.
30. Swerdlow RH. The neurodegenerative mitochondriopathies.
J Alzheimers Dis. 2009; 17(4): 737-751.
31. Liang WC, Nishino I. State of the art in muscle lipid
diseases. Acta Myol. 2010; 29(2): 351-356.
32. Petit C. Usher syndrome: from genetics to pathogenesis.
Annu Rev Genomics Hum Genet. 2001; 2: 271-297.
33. Timmons M, Tsokos M, Asab MA, Seminara SB, Zirzow
GC, Kaneski CR, Heiss JD, van der Knaap MS,
Vanier MT, Schiffmann R, Wong K. Peripheral and
central hypomyelination with hypogonadotropic hypogonadism
and hypodontia Neurology, 2006; 67(11):
2066-2069.
34. Crandall BF, Samec L, Sparkes RS. A familial syndrome
of deafness, alopecia and hypogonadism. J Pediatr.
1973; 82(3): 461-465.
35. Sohval AR, Soffer LJ. Congenital familial testicular deficiency.
Am J Med. 1953; 14(3): 328-348.
36. Woodhouse NJ, Sakati NA. A syndrome of hypogonadism,
alopecia, diabetes mellitus, mental retardation,
deafness, and ECG abnormalities. J Med Genet. 1983;
20(3): 216-219.
37. Nicolaides P, Appleton RE, Fryer A. Cerebellar ataxia,
areflexia, pes cavus, optic atrophy, and sensorineural
hearing loss (CAPOS): a new syndrome. J Med Genet.
1996; 33(5): 419-421.
38. Pierce SB, Chisholm KM, Lynch ED, Lee MK, Walsh
T, Opitz JM, Li W, Klevit RE, King MC. Mutations in
mitochondrial histidyl tRNA synthetase HARS2 cause
ovarian dysgenesis and sensorineural hearing loss of
Perrault syndrome. Proc Natl Acad Sci USA. 2011;
108(16): 6543-6548.
39. Gironi M, Lamperti C, Nemni R, Moggio M, Comi G,
Guerini FR, Ferrante P, Canal N, Naini A, Bresolin N,
DiMauro S. Late-onset cerebellar ataxia with hypogonadism
and muscle coenzyme Q10 deficiency. Neurology.
2004; 62(5): 818-820.
40. Ienco EC, Simoncini C, Orsucci D, Petrucci L, Filosto
M, Mancuso M, Siciliano G. May “mitochondrial eve”
and mitochondrial haplogroups play a role in neurodegeneration
and Alzheimer’s disease? Int J Alzheimers
Dis. 2011; 2011: 709061.
41. Leipnitz G, Amaral AU, Zanatta A, Seminotti B, Fernandes
CG, Knebel LA, Vargas CR, Wajner M. Neurochemical
evidence that phytanic acid induces oxidative
damage and reduces the antioxidant defenses in
cerebellum and cerebral cortex of rats. Life Sci. 2010;
87(9-10): 275-280.
42. Hogstrom L, Mark J. Fragile X syndrome: relation to
premature ovarian failure and infertility treatment. Acta
Obstet Gynecol Scand. 2007; 86(2): 244-246.
43. Senderek J, Krieger M, Stendel C, Bergmann C, Moser M,
Breitbach-Faller N, Rudnik-Schöneborn S, Blaschek A,
Wolf NI, Harting I, North K, Smith J, Muntoni F, Brockington
M, Quijano-Roy S, Renault F, Herrmann R, Hendershot
LM, Schröder JM, Lochmüller H, Topaloglu H, Voit
T, Weis J, Ebinger F, Zerres K. Mutations in SIL1 cause
Marinesco-Sjögren syndrome, a cerebellar ataxia with cataract
and myopathy. Nat Genet. 2005; 37(12): 1312-1314.
44. Leslie ND. Insights into the pathogenesis of galactosemia.
Annu Rev Nutr. 2003; 23: 59-80.
45. Pandolfo M. Friedreich ataxia. Arch Neurol. 2008;
65(10): 1296-1303.
46. Koutnikova H, Campuzano V, Foury F, Dolle P, Cazzalini
O, Koenig M. Studies of human, mouse and
yeast homologues indicate a mitochondrial function for
frataxin. Nat Genet. 1997; 16(4): 345-351.
47. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR,
Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial
calcium defects in Huntington’s disease are
a direct effect of polyglutamines. Nat Neurosci. 2002;
5(8): 731-736.
48. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese
N, Krainc D. Transcriptional repression of PGC-1α by
mutant huntingtin leads to mitochondrial dysfunction
and neurodegeneration. Cell. 2006; 127(1): 59-69.
49. Halpin C, Owen G, Gutiérrez-Espeleta G, Sims K,
Rehm H. Audiologic features of Norrie disease. Ann
Otol Rhinol Laryngol. 2005; 114(7): 533-538.
50. Manaviat MR, Rashidi M, Mohammadi SM. Wolfram
Syndrome presenting with optic atrophy and diabetes
mellitus: two case reports. Cases J. 2009; 2: 9355.
51. Reiners J, Nagel-Wolfrum K, Jürgens K, Märker T,
Wolfrum U. Molecular basis of human Usher syndrome:
deciphering the meshes of the Usher protein
network provides insights into the pathomechanisms of
the Usher disease. Exp Eye Res. 2006; 83(1): 97-119.
52. Kokotas H, Van Laer L, Grigoriadou M, Iliadou V,
Economides J, Pomoni S, Pampanos A, Eleftheriades
N, Ferekidou E, Korres S, Giannoulia-Karantana A,
Van Camp G, Petersen MB. Strong linkage disequilibrium
for the frequent GJB2 35delG mutation in the
Greek population. Am J Med Genet A. 2008; 146A(22):
2879-2884.
53. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered
axonal mitochondrial transport in the pathogenesis
of Charcot-Marie-Tooth disease from mitofusin 2
mutations. J Neurosci. 2007; 27(2): 422-430.
54. Schneider C, Reiners K, Toyka KV. Myotonic dystrophy
(DM/Curschmann-Steinert disease) and proximal
myotonic myopathy (PROMM/Ricker syndrome). Myotonic
muscle diseases with multisystemic manifestations.
Nervenarzt. 2001; 72(8): 618-624.
55. Badano JL, Mitsuma N, Beales PL, Katsanis N. The ciliopathies:
an emerging class of human genetic disorders.
Annu Rev Genomics Hum Genet. 2006; 7: 125-148.
56. Aguglia U, Annesi G, Pasquinelli G, Spadafora P, Gambardella
A, Annesi F, Pasqua AA, Cavalcanti F, Crescibene
L, Bagalà A, Bono F, Oliveri RL, Valentino P,
Zappia M, Quattrone A. Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren
syndrome. Ann Neurol. 2000; 47(2): 260-264.
57. Baldwin EJ, Gibberd FB, Harley C, Sidey MC, Feher
MD, Wierzbicki AS. The effectiveness of long-term dietary
therapy in the treatment of adult Refsum disease.
J Neurol Neurosurg Psychiatry. 2010; 81(9): 954-957.
58. McGuinness MC, Wei H, Smith KD. Therapeutic developments
in peroxisome biogenesis disorders. Expert
Opin Investig Drugs. 2000; 9(9): 1985-1992.
59. Perera NJ, Lewis B, Tran H, Fietz M, Sullivan DR.
Refsum’s disease-use of the intestinal lipase inhibitor,
Orlistat, as a novel therapeutic approach to a complex
disorder. J Obes. 2011; 2011.pii: Epub 2010 Sep 1.
60. Leipnitz G, Amaral AU, Zanatta A, Seminotti B, Fernandes
CG, Knebel LA, Vargas CR, Wajner M. Neurochemical
evidence that phytanic acid induces oxidative
damage and reduces the antioxidant defenses in
cerebellum and cerebral cortex of rats. Life Sci. 2010;
87(9-10): 275-280.
61. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation
in CNS health and disease: from molecular
mechanisms to therapeutic opportunities. Antioxid Redox
Signal. 2010; 12(1): 125-169.
62. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce
V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier
JF, Fontés M. Ascorbic acid treatment corrects the
phenotype of a mouse model of Charcot-Marie-Tooth
disease. Nat Med. 2004; 10(4): 396-401.
63. Williams DS. Usher syndrome: animal models, retinal
function of Usher proteins, and prospects for gene therapy.
Vision Res. 2008; 48(3): 433-441.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
